Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Lexaria Bioscience ( (LEXX) ) just unveiled an announcement.
Lexaria Bioscience has announced promising results from its human clinical study comparing oral DehydraTECH-liraglutide capsules to the injected form of liraglutide, Saxenda®. The study showed a significant reduction in adverse events with the oral formulation, particularly in nausea and gastrointestinal issues, and met its primary endpoint of demonstrating safety and tolerability. These findings suggest a potential pathway for FDA registration of an oral version of liraglutide, addressing an unmet market need and offering a competitive alternative to existing injectable forms.
The most recent analyst rating on (LEXX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Lexaria Bioscience stock, see the LEXX Stock Forecast page.
More about Lexaria Bioscience
Lexaria Bioscience Corp. is a global innovator in drug delivery platforms, focusing on enhancing the delivery and effectiveness of drugs using its patented DehydraTECH technology. The company is involved in the pharmaceutical industry, specifically targeting the delivery of GLP-1 drugs, which are used for treating conditions like diabetes and obesity.
Average Trading Volume: 94,078
Technical Sentiment Signal: Sell
Current Market Cap: $20.46M
For detailed information about LEXX stock, go to TipRanks’ Stock Analysis page.